TuHURA Biosciences (HURA) AI Stock Analysis

• Market Cap: $149.26M
• Dividend Yield: N/A
• Average Volume (3M): 257.50K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.27
• Revenue Growth: N/A
• EPS Growth: 77.15%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -75.23
• Shares Outstanding: 42,284,523
• 10 Day Avg. Volume: 428,298
• 30 Day Avg. Volume: 257,496
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -18.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.00
• Price Target Upside: 268.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

TuHURA Biosciences scores low overall due to severe financial instability, reflected in negative cash flows, net losses, and a negative P/E ratio. While technical analysis shows some short-term positive momentum, risks are substantial. The company's strategic acquisitions and product innovations offer potential, but financial health remains a critical concern.

TuHURA Biosciences Business Overview & Revenue Model

Company Description

TuHURA Biosciences (HURA) is a pioneering biotechnology company focused on the research and development of advanced therapeutic solutions. Operating in the biopharmaceutical sector, the company specializes in utilizing cutting-edge technologies such as genomics and artificial intelligence to develop novel treatments for complex diseases. TuHURA Biosciences is committed to transforming patient outcomes through innovative drug discovery and development processes.

How the Company Makes Money

TuHURA Biosciences generates revenue primarily through the development and commercialization of proprietary drugs and therapies. The company's revenue streams include licensing agreements with pharmaceutical companies, which provide upfront payments, milestone payments, and royalties based on sales of licensed products. Additionally, TuHURA engages in strategic partnerships and collaborations with other biotech firms and research institutions to co-develop new therapies, sharing both costs and revenues. Government grants and research funding also contribute to the company's income, supporting its ongoing research initiatives and clinical trials. Revenue is further bolstered by providing contract research services to other organizations in the biotech and pharmaceutical sectors.

TuHURA Biosciences Financial Statement Overview

Summary

TuHURA Biosciences is facing severe financial challenges, with no revenue generation and increasing net losses. The balance sheet reflects significant financial instability, and cash flow statements indicate ongoing cash burn problems. The company appears to be heavily reliant on external financing to maintain operations, posing substantial risks to its long-term viability.

Income Statement

TuHURA Biosciences has consistently reported zero revenue, indicating challenges in commercializing its products or services. The company faces increasing net losses, with a substantial net profit margin decline. The negative EBIT and EBITDA margins highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet reveals a troubling negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, but high liabilities relative to assets suggest significant leverage. The equity ratio is negative, further emphasizing financial distress.

Cash Flow

Cash flow analysis shows negative operating and free cash flows over time, highlighting cash burn issues. The company is not generating sufficient cash from operations to sustain itself, relying heavily on financing activities for liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-15.00K	0.00	0.00	0.00	-32.00K	-10.00K
	EBIT
-7.83M	-29.76M	-9.93M	-7.25M	-21.57M	-8.14M
	EBITDA
-7.75M	-29.12M	-9.56M	-6.01M	-38.15M	-9.12M
	Net Income Common Stockholders
-8.03M	-29.32M	-9.37M	-7.02M	-38.30M	-9.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.46M	3.67M	14.25M	5.55M	10.54M	2.39M
	Total Assets
5.79M	4.36M	15.20M	6.40M	13.54M	2.94M
	Total Debt
7.16M	2.34M	138.22K	644.07K	0.00	0.00
	Net Debt
2.69M	-1.32M	-14.11M	-4.90M	-10.54M	-2.39M
	Total Liabilities
11.85M	5.92M	2.89M	7.15M	2.96M	2.67M
	Stockholders Equity
-6.07M	-1.56M	12.30M	-747.82K	10.58M	263.00K
Cash Flow		Free Cash Flow
-7.86M	-12.03M	-7.54M	-6.57M	-18.87M	-7.93M
	Operating Cash Flow
-7.84M	-11.95M	-7.51M	-6.56M	-18.86M	-7.93M
	Investing Cash Flow
-20.00K	-1.30M	-36.28K	-3.28K	964.00K	0.00
	Financing Cash Flow
7.21M	2.66M	16.25M	7.04M	26.04M	6.60M

TuHURA Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Neutral. The current price of 3.53 is above the 20-day moving average (MA) of 2.76, below the 50-day MA of 3.56, and below the 200-day MA of 5.72, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 55.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HURA.

TuHURA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	80 Outperform	$10.27B	20.71	23.13%	―	18.49%	176.71%
VRTX	64 Neutral	$126.52B	―	-3.15%	―	11.64%	-114.72%
IONS	49 Neutral	$4.95B	―	-93.03%	―	-10.48%	-18.79%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%
BLUE	39 Underperform	$39.74M	―	-295.35%	―	184.12%	31.92%
HURA	34 Underperform	$149.26M	―	1880.80%	―	―	77.15%

TuHURA Biosciences Corporate Events

TuHURA Biosciences to Acquire Kineta, Inc. in 2025

TuHURA Biosciences has entered into a definitive merger agreement to acquire Kineta, Inc., a clinical-stage biotechnology company. This strategic acquisition includes Kineta’s novel KVA12123 antibody and is expected to enhance TuHURA’s late-stage pipeline with potential synergies in cancer immunotherapy. The merger is anticipated to close in the first quarter of 2025, pending certain approvals and conditions, which could significantly impact TuHURA’s operations and market position by expanding its capabilities in developing treatments for blood-related cancers.

TuHURA Biosciences Advances in Cancer Immunotherapy Innovations

TuHURA Biosciences, Inc. is making significant strides in cancer immunotherapy with its IFx-2.0 technology, set to undergo a Phase 3 trial in advanced Merkel Cell Carcinoma. The company has entered a non-binding letter of intent to acquire Kineta’s innovative VISTA inhibiting antibody, KVA12123, to enhance its treatment pipeline. TuHURA’s strategic advancements include novel bi-specific antibodies and mRNA technologies, aiming to overcome resistance to current cancer immunotherapies. Key leadership hires aim to bolster clinical and operational execution as the company targets ambitious milestones for 2024-2025.

TuHURA Biosciences Announces Executive Salary and Stock Options

TuHURA Biosciences, Inc. has announced significant salary increases for its CEO, James A. Bianco, and CFO, Dan Dearborn, effective from January 2025, aligning their compensation with industry standards. Additionally, both executives received stock option awards as part of the 2024 Equity Incentive Plan, offering potential long-term gains tied to the company’s stock performance, with the options vesting over three years.